Cargando…
Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach
The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417724/ https://www.ncbi.nlm.nih.gov/pubmed/32588533 http://dx.doi.org/10.1111/jcmm.15546 |
_version_ | 1783569557232812032 |
---|---|
author | Schneidewind, Laila Neumann, Thomas Krüger, William Hakenberg, Oliver Walther Schmidt, Christian A. |
author_facet | Schneidewind, Laila Neumann, Thomas Krüger, William Hakenberg, Oliver Walther Schmidt, Christian A. |
author_sort | Schneidewind, Laila |
collection | PubMed |
description | The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme‐linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL‐11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL‐11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 10(6) copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL‐11. |
format | Online Article Text |
id | pubmed-7417724 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74177242020-08-11 Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach Schneidewind, Laila Neumann, Thomas Krüger, William Hakenberg, Oliver Walther Schmidt, Christian A. J Cell Mol Med Original Articles The BK polyomavirus (BKPyV) has pathogenic relevance especially in immunocompromised patients. No causal therapy has been established yet. Therefore, new therapeutic targets need to be identified in experimental studies. A 3D organotypic cell culture model with primary urothelial cells and fibroblasts was used as infection model. The detection of virus replication was performed with quantitative polymerase chain reaction (qPCR), and immunohistochemistry (IHC) was also used for analysis. Interleukin levels were measured by enzyme‐linked immunosorbent assay (ELISA). Interestingly, the signal transducer and activator of transcription 3 (STAT3) pathway seems to be activated during infection with BKPyV, for example phosphorylated STAT3 is significantly (P < 0.0001) elevated on day 6 following infection. Therefore, we performed ELISAs for involved interleukins in STAT3 pathway. Interleukin 11 (IL‐11) was significantly (P = 0.026) elevated at day 9. Subsequently, 3D cultures were treated with IL‐11 neutralizing antibody. At day 9 following infection, the median virus replication rate is 4.4 × 10(6) copies/ml. The difference to replication rate without treatment was significantly lower at day 6 (P < 0.0001) and at day 9 (P < 0.0001), respectively. STAT3 pathways seem to be involved during BKPyV infection and need further investigation in experimental studies. A very promising target for treatment might be IL‐11. John Wiley and Sons Inc. 2020-06-25 2020-08 /pmc/articles/PMC7417724/ /pubmed/32588533 http://dx.doi.org/10.1111/jcmm.15546 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Schneidewind, Laila Neumann, Thomas Krüger, William Hakenberg, Oliver Walther Schmidt, Christian A. Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title | Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title_full | Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title_fullStr | Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title_full_unstemmed | Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title_short | Targeting IL‐11 in the treatment of BK virus‐associated haemorrhagic cystitis—A promising new approach |
title_sort | targeting il‐11 in the treatment of bk virus‐associated haemorrhagic cystitis—a promising new approach |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417724/ https://www.ncbi.nlm.nih.gov/pubmed/32588533 http://dx.doi.org/10.1111/jcmm.15546 |
work_keys_str_mv | AT schneidewindlaila targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach AT neumannthomas targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach AT krugerwilliam targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach AT hakenbergoliverwalther targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach AT schmidtchristiana targetingil11inthetreatmentofbkvirusassociatedhaemorrhagiccystitisapromisingnewapproach |